Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes

被引:9
作者
Hyslop, Terry [1 ]
Weinberg, David S. [2 ]
Schulz, Stephanie [1 ]
Barkun, Alan [3 ]
Waldman, Scott A. [1 ]
机构
[1] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA
[2] Fox Chase Canc Ctr, Dept Med, Philadelphia, PA 19111 USA
[3] McGill Univ, Dept Med, Div Gastroenterol, Montreal, PQ, Canada
基金
美国国家卫生研究院;
关键词
racial disparities; colorectal cancer; molecular staging; occult tumor burden; guanylyl cyclase C; RT-qPCR; GUANYLYL CYCLASE-C; COLON-CANCER; LYMPH-NODES; MICROSATELLITE INSTABILITY; AFRICAN-AMERICANS; SURVIVAL; RACE; MICROMETASTASES; MORTALITY; CARCINOMA;
D O I
10.1002/cncr.26516
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: There are differences in outcomes in blacks compared with whites with lymph nodenegative (pN0) colorectal cancer. Recurrence in pN0 patients suggests the presence of occult metastases undetected by conventional approaches. This study explores the association of racial differences in outcomes with occult tumor burden in regional lymph nodes.METHODS: Lymph nodes (range, 2-159) from 282 prospectively enrolled pN0 colorectal cancer patients followed for a median of 24 months (range, 2-63 months) were subjected to molecular analysis. Occult tumor burden was estimated by quantifying the expression of GUCY2C, a biomarker for metastatic colorectal cancer cells. Risk categories defined using occult tumor burden was the primary outcome measure. Association of prognostic variables and risk were defined by multivariate polytomous logistic regression. RESULTS: Occult tumor burden stratified this cohort of 259 whites and 23 blacks into categories with low (60%; recurrence rate [ RR] 2.3%; 95% confidence interval [ CI], 0.1%-4.5%), intermediate (31%; RR 33.3%; 95% CI, 23.7%-44.1%), and high (9%; RR 68.0%; 95% CI, 46.5%-85.1%; P < .001) risk. Blacks compared with whites exhibited 4-fold greater occult metastases in individual lymph nodes (P <.001). Multivariate analysis revealed that race (P = .02), T stage (P = .02), and number of lymph nodes collected (P = .003) were independent prognostic markers of risk category. Blacks compared with whites were more likely to harbor levels of occult tumor burden, associated with the highest recurrence risk (adjusted odds ratio 5.08; 95% CI, 1.69-21.39; P = .007). CONCLUSIONS: Racial disparities in stage-specific outcomes in colorectal cancer are associated with differences in occult tumor burden in regional lymph nodes. Cancer 2012;118:253240. (C) 2011 American Cancer Society.
引用
收藏
页码:2532 / 2540
页数:9
相关论文
共 51 条
  • [11] Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer
    Cagir, B
    Gelmann, A
    Park, J
    Fava, T
    Tankelevitch, A
    Bittner, EW
    Weaver, EJ
    Palazzo, JP
    Weinberg, D
    Fry, RD
    Waldman, SA
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (11) : 805 - +
  • [12] Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues
    Carrithers, SL
    Barber, MT
    Biswas, S
    Parkinson, SJ
    Park, PK
    Goldstein, SD
    Waldman, SA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) : 14827 - 14832
  • [13] Chen VW, 1997, CANCER EPIDEM BIOMAR, V6, P1087
  • [14] Relative quantification based on logistic models for individual polymerase chain reactions
    Chervoneva, Inna
    Li, Yanyan
    Iglewicz, Boris
    Waldman, Scott
    Hyslop, Terry
    [J]. STATISTICS IN MEDICINE, 2007, 26 (30) : 5596 - 5611
  • [15] Differences in colorectal carcinoma stage and survival by race and ethnicity
    Chien, C
    Morimoto, LM
    Tom, J
    Li, CI
    [J]. CANCER, 2005, 104 (03) : 629 - 639
  • [16] The staging of colorectal cancer: 2004 and beyond
    Compton, CC
    Greene, FL
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (06) : 295 - 308
  • [17] Colorectal cancer
    Cunningham, David
    Atkin, Wendy
    Lenz, Heinz-Josef
    Lynch, Henry T.
    Minsky, Bruce
    Nordlinger, Bernard
    Starling, Naureen
    [J]. LANCET, 2010, 375 (9719) : 1030 - 1047
  • [18] Edge SB., 2009, AJCC cancer staging manual, V7th
  • [19] Freeman HP, 1998, CANCER, V82, P219, DOI 10.1002/(SICI)1097-0142(19980101)82:1<219::AID-CNCR27>3.0.CO
  • [20] 2-4